Diffuse large B-cell lymphoma (DLBCL) was considered an incurable disease until the introduction of polychemotherapy (e.g., CHOP) in the 1970s. Treatment improved significantly with the introduction of the anti-CD20 antibody, rituximab, in combination with CHOP (R-CHOP), however, one-third of patients are either refractory to this initial treatment or relapse after treatment. Prof Laurie Sehn chaired a symposium as part of the 15th International Congress on Malignant Lymphoma (ICML) in Lugano, Switzerland, discussing the unmet need of DLBCL patients and the future of using antibody therapy.
Latest articles
All articles
